CYDY News and Press, CytoDyn Inc From 10/20/21

2021 Annual Meeting Will be Held as Scheduled on October 28, 2021 CytoDyn Urges Shareholders to Vote on Company’s BLUE Proxy Card to Ensure their Vote Counts All Proxies and Votes in Favor of the Activist Group’s Nominees Will be Disregarded Cyt...

Urges Shareholders to Ensure that Their Vote Counts Proxies and Votes in Favor of the Activist Group’s Nominees Will be Disregarded Shareholders Will Receive Company Proxy Material this Week CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the &#...

A group of long-time stockholders (the “Investor Group”) of CytoDyn Inc. (“CYDY” or the “Company”) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today commented on the decision...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Plowing through the most populated regions of the world like a hurricane, the novel coronavirus was and still is an unrelenting force. According to the time of writing data from Worldometers.info, 4.86 million people succum...

Affirms that Nomination Notice Failed to Comply with Company’s By-laws Proxies and Votes in Favor of the Activist Group’s Nominees Will be Disregarded Company Will Immediately File Its Definitive Proxy Statement CytoDyn Inc. (OTCQB: CYDY) ( ...

Clinical Trial Development Targeting Triple-Negative Breast Cancer (TNBC) to Evaluate Anti-Tumor Effects and Identify Immunological Biomarkers for Leronlimab in Combination with Immune Checkpoint Blockade VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB...

New hires in Bioanalytical Sciences, Biostatistics, Clinical Regulatory, and Clinical Project Management will join the team of Drs. Srinivasan, Recknor, Ray, and Kelly to lead all clinical trials with new CROs VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (...

All clinical activities have been moved away from Amarex; a complete update on all activities will be provided to shareholders next week by Drs. Recknor, Kelly, Ray, and Pourhassan VANCOUVER, Washington, Oct. 07, 2021 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or ...

CytoDyn continues to match leronlimab up against COVID-19. The company recently started two clinical trials in Brazil where the pandemic endures. If the Brazilian trials hit their endpoints, CytoDyn could file for EUAs in several countries. I expect these trials to produce better resu...

Company Is Successfully Executing on Multi-Faceted Strategy to Bring Leronlimab to Market Activist Group Offers No New Compelling Strategic Direction and its “Plan” Includes Numerous Misrepresentations and Misleading Statements Activist Group’s Con...